Target Gene/Pathway(薬物標的遺伝子/パスウェイリスト)
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z other
No. | KEGG PATHWAY * On map, Yellow: Drug target, Red: Disease-related |
KEGG GENES * | KEGG DRUG * | DrugBank | 指定難病告示番号 * |
1 | Acute myeloid leukemia |
1件: KIT | D10229 | Masitinib | 6件: 2, 5, 6, 13, 46, 96 |
2 | Adrenergic signaling in cardiomyocytes |
5件: ADRA1A, ADRA1B, ADRA1D, ADRB1, ADRB2 | D01277 | Droxidopa | 3件: 5, 6, 17 |
3 | Alanine, aspartate and glutamate metabolism |
4件: ABAT, ALDH5A1, GAD1, GAD2 | D00399 | Valproic Acid | 14件: 2, 3, 5, 8, 26, 34, 65, 89, 90, 102, 222, 233, 256, 331 |
4 | Alcoholism |
5件: GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D | D00775 | Riluzole | 7件: 2, 3, 5, 8, 13, 17, 206 |
1件: MAOB | D02562 | Rasagiline | 4件: 2, 5, 6, 17 | ||
D08469 | |||||
D10829 | |||||
5 | Aldosterone synthesis and secretion |
3件: CACNA1G, CACNA1H, CACNA1I | D00399 | Valproic Acid | 14件: 2, 3, 5, 8, 26, 34, 65, 89, 90, 102, 222, 233, 256, 331 |
6 | Alzheimer disease |
5件: GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D | D00775 | Riluzole | 7件: 2, 3, 5, 8, 13, 17, 206 |
7 | Amphetamine addiction |
9件: GRIA1, GRIA2, GRIA3, GRIA4, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D | D00775 | Riluzole | 7件: 2, 3, 5, 8, 13, 17, 206 |
1件: MAOB | D02562 | Rasagiline | 4件: 2, 5, 6, 17 | ||
D08469 | |||||
D10829 | |||||
8 | AMPK signaling pathway |
1件: ADRA1A | D01277 | Droxidopa | 3件: 5, 6, 17 |
9 | Amyotrophic lateral sclerosis (ALS) |
7件: GRIA1, GRIA2, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D | D00775 | Riluzole | 7件: 2, 3, 5, 8, 13, 17, 206 |
10 | Arachidonic acid metabolism |
2件: PTGS1, PTGS2 | D00428 | Salsalate | 1件: 5 |
11 | Arginine and proline metabolism |
1件: MAOB | D02562 | Rasagiline | 4件: 2, 5, 6, 17 |
D08469 | |||||
D10829 | |||||
12 | beta-Alanine metabolism |
3件: ABAT, GAD1, GAD2 | D00399 | Valproic Acid | 14件: 2, 3, 5, 8, 26, 34, 65, 89, 90, 102, 222, 233, 256, 331 |
13 | Breast cancer |
1件: KIT | D10229 | Masitinib | 6件: 2, 5, 6, 13, 46, 96 |
14 | Butanoate metabolism |
4件: ABAT, ALDH5A1, GAD1, GAD2 | D00399 | Valproic Acid | 14件: 2, 3, 5, 8, 26, 34, 65, 89, 90, 102, 222, 233, 256, 331 |
15 | C-type lectin receptor signaling pathway |
1件: PTGS2 | D00428 | Salsalate | 1件: 5 |
16 | Calcium signaling pathway |
6件: ADRA1A, ADRA1B, ADRA1D, ADRB1, ADRB2, ADRB3 | D01277 | Droxidopa | 3件: 5, 6, 17 |
3件: CACNA1G, CACNA1H, CACNA1I | D00399 | Valproic Acid | 14件: 2, 3, 5, 8, 26, 34, 65, 89, 90, 102, 222, 233, 256, 331 | ||
4件: CHRM1, CHRM2, CHRM3, CHRM5 | D00787 | Trihexyphenidyl | 2件: 5, 6 | ||
D08638 | |||||
4件: GRIN1, GRIN2A, GRIN2C, GRIN2D | D00775 | Riluzole | 7件: 2, 3, 5, 8, 13, 17, 206 | ||
17 | cAMP signaling pathway |
2件: ADRB1, ADRB2 | D01277 | Droxidopa | 3件: 5, 6, 17 |
2件: CHRM1, CHRM2 | D00787 | Trihexyphenidyl | 2件: 5, 6 | ||
D08638 | |||||
9件: GRIA1, GRIA2, GRIA3, GRIA4, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D | D00775 | Riluzole | 7件: 2, 3, 5, 8, 13, 17, 206 | ||
18 | Central carbon metabolism in cancer |
1件: KIT | D10229 | Masitinib | 6件: 2, 5, 6, 13, 46, 96 |
19 | cGMP-PKG signaling pathway |
9件: ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3 | D01277 | Droxidopa | 3件: 5, 6, 17 |
20 | Chemical carcinogenesis |
1件: PTGS2 | D00428 | Salsalate | 1件: 5 |
21 | Cholinergic synapse |
1件: ACHE | D00670 | Donepezil | 9件: 5, 6, 13, 46, 78, 124, 127, 156, 206 |
D07869 | |||||
D02558 | Rivastigmine | 3件: 5, 6, 13 | |||
D03822 | |||||
5件: CHRM1, CHRM2, CHRM3, CHRM4, CHRM5 | D00787 | Trihexyphenidyl | 2件: 5, 6 | ||
D08638 | |||||
22 | Circadian entrainment |
3件: CACNA1G, CACNA1H, CACNA1I | D00399 | Valproic Acid | 14件: 2, 3, 5, 8, 26, 34, 65, 89, 90, 102, 222, 233, 256, 331 |
9件: GRIA1, GRIA2, GRIA3, GRIA4, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D | D00775 | Riluzole | 7件: 2, 3, 5, 8, 13, 17, 206 | ||
23 | Cocaine addiction |
6件: GRIA2, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D | D00775 | Riluzole | 7件: 2, 3, 5, 8, 13, 17, 206 |
1件: MAOB | D02562 | Rasagiline | 4件: 2, 5, 6, 17 | ||
D08469 | |||||
D10829 | |||||
24 | Cortisol synthesis and secretion |
3件: CACNA1G, CACNA1H, CACNA1I | D00399 | Valproic Acid | 14件: 2, 3, 5, 8, 26, 34, 65, 89, 90, 102, 222, 233, 256, 331 |
25 | Cushing syndrome |
3件: CACNA1G, CACNA1H, CACNA1I | D00399 | Valproic Acid | 14件: 2, 3, 5, 8, 26, 34, 65, 89, 90, 102, 222, 233, 256, 331 |
26 | Dilated cardiomyopathy (DCM) |
1件: ADRB1 | D01277 | Droxidopa | 3件: 5, 6, 17 |
27 | Dopaminergic synapse |
6件: GRIA1, GRIA2, GRIA3, GRIA4, GRIN2A, GRIN2B | D00775 | Riluzole | 7件: 2, 3, 5, 8, 13, 17, 206 |
1件: MAOB | D02562 | Rasagiline | 4件: 2, 5, 6, 17 | ||
D08469 | |||||
D10829 | |||||
28 | Drug metabolism - cytochrome P450 |
1件: MAOB | D02562 | Rasagiline | 4件: 2, 5, 6, 17 |
D08469 | |||||
D10829 | |||||
29 | GABAergic synapse |
3件: ABAT, GAD1, GAD2 | D00399 | Valproic Acid | 14件: 2, 3, 5, 8, 26, 34, 65, 89, 90, 102, 222, 233, 256, 331 |
16件: GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ | D00706 | Zolpidem | 2件: 5, 6 | ||
D08690 | |||||
30 | Gap junction |
1件: ADRB1 | D01277 | Droxidopa | 3件: 5, 6, 17 |
31 | Gastric acid secretion |
1件: CHRM3 | D00787 | Trihexyphenidyl | 2件: 5, 6 |
D08638 | |||||
32 | Glutamatergic synapse |
14件: GRIA1, GRIA2, GRIA3, GRIA4, GRIK1, GRIK2, GRIK3, GRIK4, GRIK5, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D | D00775 | Riluzole | 7件: 2, 3, 5, 8, 13, 17, 206 |
33 | Glycerophospholipid metabolism |
1件: ACHE | D00670 | Donepezil | 9件: 5, 6, 13, 46, 78, 124, 127, 156, 206 |
D07869 | |||||
D02558 | Rivastigmine | 3件: 5, 6, 13 | |||
D03822 | |||||
34 | Glycine, serine and threonine metabolism |
1件: MAOB | D02562 | Rasagiline | 4件: 2, 5, 6, 17 |
D08469 | |||||
D10829 | |||||
35 | GnRH secretion |
3件: CACNA1G, CACNA1H, CACNA1I | D00399 | Valproic Acid | 14件: 2, 3, 5, 8, 26, 34, 65, 89, 90, 102, 222, 233, 256, 331 |
36 | Hematopoietic cell lineage |
1件: KIT | D10229 | Masitinib | 6件: 2, 5, 6, 13, 46, 96 |
37 | Histidine metabolism |
1件: MAOB | D02562 | Rasagiline | 4件: 2, 5, 6, 17 |
D08469 | |||||
D10829 | |||||
38 | Human cytomegalovirus infection |
1件: PTGS2 | D00428 | Salsalate | 1件: 5 |
39 | Human papillomavirus infection |
1件: PTGS2 | D00428 | Salsalate | 1件: 5 |
40 | Huntington disease |
2件: GRIN1, GRIN2B | D00775 | Riluzole | 7件: 2, 3, 5, 8, 13, 17, 206 |
41 | IL-17 signaling pathway |
1件: PTGS2 | D00428 | Salsalate | 1件: 5 |
42 | Insulin secretion |
1件: CHRM3 | D00787 | Trihexyphenidyl | 2件: 5, 6 |
D08638 | |||||
1件: SNAP25 | D00783 | Botulinum toxin type A | 13件: 2, 5, 6, 7, 13, 15, 17, 36, 51, 70, 113, 149, 226 | ||
43 | Kaposi sarcoma-associated herpesvirus infection |
1件: PTGS2 | D00428 | Salsalate | 1件: 5 |
44 | Leishmaniasis |
1件: PTGS2 | D00428 | Salsalate | 1件: 5 |
45 | Long-term depression |
3件: GRIA1, GRIA2, GRIA3 | D00775 | Riluzole | 7件: 2, 3, 5, 8, 13, 17, 206 |
46 | Long-term potentiation |
7件: GRIA1, GRIA2, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D | D00775 | Riluzole | 7件: 2, 3, 5, 8, 13, 17, 206 |
47 | MAPK signaling pathway |
3件: CACNA1G, CACNA1H, CACNA1I | D00399 | Valproic Acid | 14件: 2, 3, 5, 8, 26, 34, 65, 89, 90, 102, 222, 233, 256, 331 |
1件: KIT | D10229 | Masitinib | 6件: 2, 5, 6, 13, 46, 96 | ||
48 | Melanogenesis |
1件: KIT | D10229 | Masitinib | 6件: 2, 5, 6, 13, 46, 96 |
49 | Metabolic pathways |
4件: ABAT, ALDH5A1, GAD1, GAD2 | D00399 | Valproic Acid | 14件: 2, 3, 5, 8, 26, 34, 65, 89, 90, 102, 222, 233, 256, 331 |
1件: MAOB | D02562 | Rasagiline | 4件: 2, 5, 6, 17 | ||
D08469 | |||||
D10829 | |||||
2件: PTGS1, PTGS2 | D00428 | Salsalate | 1件: 5 | ||
50 | MicroRNAs in cancer |
1件: PTGS2 | D00428 | Salsalate | 1件: 5 |
51 | Morphine addiction |
16件: GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ | D00706 | Zolpidem | 2件: 5, 6 |
D08690 | |||||
52 | Neuroactive ligand-receptor interaction |
9件: ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3 | D01277 | Droxidopa | 3件: 5, 6, 17 |
5件: CHRM1, CHRM2, CHRM3, CHRM4, CHRM5 | D00787 | Trihexyphenidyl | 2件: 5, 6 | ||
D08638 | |||||
16件: GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ | D00706 | Zolpidem | 2件: 5, 6 | ||
D08690 | |||||
14件: GRIA1, GRIA2, GRIA3, GRIA4, GRIK1, GRIK2, GRIK3, GRIK4, GRIK5, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D | D00775 | Riluzole | 7件: 2, 3, 5, 8, 13, 17, 206 | ||
2件: HCRTR1, HCRTR2 | D10082 | Suvorexant | 3件: 5, 6, 13 | ||
53 | NF-kappa B signaling pathway |
1件: PTGS2 | D00428 | Salsalate | 1件: 5 |
54 | Nicotine addiction |
16件: GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ | D00706 | Zolpidem | 2件: 5, 6 |
D08690 | |||||
9件: GRIA1, GRIA2, GRIA3, GRIA4, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D | D00775 | Riluzole | 7件: 2, 3, 5, 8, 13, 17, 206 | ||
55 | Ovarian steroidogenesis |
1件: PTGS2 | D00428 | Salsalate | 1件: 5 |
56 | Oxytocin signaling pathway |
1件: PTGS2 | D00428 | Salsalate | 1件: 5 |
57 | Pancreatic secretion |
1件: CHRM3 | D00787 | Trihexyphenidyl | 2件: 5, 6 |
D08638 | |||||
58 | Pathways in cancer |
1件: KIT | D10229 | Masitinib | 6件: 2, 5, 6, 13, 46, 96 |
1件: PTGS2 | D00428 | Salsalate | 1件: 5 | ||
59 | Phenylalanine metabolism |
1件: MAOB | D02562 | Rasagiline | 4件: 2, 5, 6, 17 |
D08469 | |||||
D10829 | |||||
60 | Phospholipase D signaling pathway |
1件: KIT | D10229 | Masitinib | 6件: 2, 5, 6, 13, 46, 96 |
61 | PI3K-Akt signaling pathway |
2件: CHRM1, CHRM2 | D00787 | Trihexyphenidyl | 2件: 5, 6 |
D08638 | |||||
1件: KIT | D10229 | Masitinib | 6件: 2, 5, 6, 13, 46, 96 | ||
62 | Platelet activation |
1件: PTGS1 | D00428 | Salsalate | 1件: 5 |
63 | Propanoate metabolism |
1件: ABAT | D00399 | Valproic Acid | 14件: 2, 3, 5, 8, 26, 34, 65, 89, 90, 102, 222, 233, 256, 331 |
64 | Rap1 signaling pathway |
3件: GRIN1, GRIN2A, GRIN2B | D00775 | Riluzole | 7件: 2, 3, 5, 8, 13, 17, 206 |
1件: KIT | D10229 | Masitinib | 6件: 2, 5, 6, 13, 46, 96 | ||
65 | Ras signaling pathway |
3件: GRIN1, GRIN2A, GRIN2B | D00775 | Riluzole | 7件: 2, 3, 5, 8, 13, 17, 206 |
1件: KIT | D10229 | Masitinib | 6件: 2, 5, 6, 13, 46, 96 | ||
66 | Regulation of actin cytoskeleton |
5件: CHRM1, CHRM2, CHRM3, CHRM4, CHRM5 | D00787 | Trihexyphenidyl | 2件: 5, 6 |
D08638 | |||||
67 | Regulation of lipolysis in adipocytes |
3件: ADRB1, ADRB2, ADRB3 | D01277 | Droxidopa | 3件: 5, 6, 17 |
2件: PTGS1, PTGS2 | D00428 | Salsalate | 1件: 5 | ||
68 | Renin secretion |
3件: ADRB1, ADRB2, ADRB3 | D01277 | Droxidopa | 3件: 5, 6, 17 |
69 | Retrograde endocannabinoid signaling |
16件: GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ | D00706 | Zolpidem | 2件: 5, 6 |
D08690 | |||||
4件: GRIA1, GRIA2, GRIA3, GRIA4 | D00775 | Riluzole | 7件: 2, 3, 5, 8, 13, 17, 206 | ||
1件: PTGS2 | D00428 | Salsalate | 1件: 5 | ||
70 | Salivary secretion |
6件: ADRA1A, ADRA1B, ADRA1D, ADRB1, ADRB2, ADRB3 | D01277 | Droxidopa | 3件: 5, 6, 17 |
1件: CHRM3 | D00787 | Trihexyphenidyl | 2件: 5, 6 | ||
D08638 | |||||
71 | Serotonergic synapse |
3件: GABRB1, GABRB2, GABRB3 | D00706 | Zolpidem | 2件: 5, 6 |
D08690 | |||||
1件: MAOB | D02562 | Rasagiline | 4件: 2, 5, 6, 17 | ||
D08469 | |||||
D10829 | |||||
2件: PTGS1, PTGS2 | D00428 | Salsalate | 1件: 5 | ||
72 | Small cell lung cancer |
1件: PTGS2 | D00428 | Salsalate | 1件: 5 |
73 | Synaptic vesicle cycle |
1件: SNAP25 | D00783 | Botulinum toxin type A | 13件: 2, 5, 6, 7, 13, 15, 17, 36, 51, 70, 113, 149, 226 |
74 | Systemic lupus erythematosus |
2件: GRIN2A, GRIN2B | D00775 | Riluzole | 7件: 2, 3, 5, 8, 13, 17, 206 |
75 | Taste transduction |
1件: CHRM3 | D00787 | Trihexyphenidyl | 2件: 5, 6 |
D08638 | |||||
6件: GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6 | D00706 | Zolpidem | 2件: 5, 6 | ||
D08690 | |||||
76 | Taurine and hypotaurine metabolism |
2件: GAD1, GAD2 | D00399 | Valproic Acid | 14件: 2, 3, 5, 8, 26, 34, 65, 89, 90, 102, 222, 233, 256, 331 |
77 | Thermogenesis |
1件: ADRB3 | D01277 | Droxidopa | 3件: 5, 6, 17 |
78 | TNF signaling pathway |
1件: PTGS2 | D00428 | Salsalate | 1件: 5 |
79 | Transcriptional misregulation in cancer |
1件: GRIA3 | D00775 | Riluzole | 7件: 2, 3, 5, 8, 13, 17, 206 |
80 | Tryptophan metabolism |
1件: MAOB | D02562 | Rasagiline | 4件: 2, 5, 6, 17 |
D08469 | |||||
D10829 | |||||
81 | Type I diabetes mellitus |
2件: GAD1, GAD2 | D00399 | Valproic Acid | 14件: 2, 3, 5, 8, 26, 34, 65, 89, 90, 102, 222, 233, 256, 331 |
82 | Type II diabetes mellitus |
1件: CACNA1G | D00399 | Valproic Acid | 14件: 2, 3, 5, 8, 26, 34, 65, 89, 90, 102, 222, 233, 256, 331 |
83 | Tyrosine metabolism |
1件: MAOB | D02562 | Rasagiline | 4件: 2, 5, 6, 17 |
D08469 | |||||
D10829 | |||||
84 | Valine, leucine and isoleucine degradation |
1件: ABAT | D00399 | Valproic Acid | 14件: 2, 3, 5, 8, 26, 34, 65, 89, 90, 102, 222, 233, 256, 331 |
85 | Vascular smooth muscle contraction |
3件: ADRA1A, ADRA1B, ADRA1D | D01277 | Droxidopa | 3件: 5, 6, 17 |
86 | VEGF signaling pathway |
1件: PTGS2 | D00428 | Salsalate | 1件: 5 |